Show simple item record

dc.rights.licenseopenen_US
dc.contributor.authorRYOM, L.
dc.contributor.authorDILLING LUNDGREN, J.
dc.contributor.authorREISS, P.
dc.contributor.authorKIRK, O.
dc.contributor.authorLAW, M.
dc.contributor.authorROSS, M.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMORLAT, Philippe
dc.contributor.authorANDREAS FUX, C.
dc.contributor.authorFONTAS, E.
dc.contributor.authorDE WIT, S.
dc.contributor.authorD'ARMINIO MONFORTE, A.
dc.contributor.authorEL-SADR, W.
dc.contributor.authorPHILLIPS, A.
dc.contributor.authorINGRID HATLEBERG, C.
dc.contributor.authorSABIN, C.
dc.contributor.authorMOCROFT, A.
dc.date.accessioned2020-07-13T10:05:40Z
dc.date.available2020-07-13T10:05:40Z
dc.date.issued2019-10-08
dc.identifier.issn0022-1899en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10425
dc.description.abstractEnBACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD. CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.
dc.language.isoENen_US
dc.subject.enMORPH3Eus
dc.title.enUse of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study
dc.title.alternativeJ Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/infdis/jiz369en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31504669en_US
bordeaux.journalThe Journal of infectious diseasesen_US
bordeaux.page1629-1634en_US
bordeaux.volume220en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue10en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-02898044
hal.version1
hal.date.transferred2020-07-13T10:05:45Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.date=2019-10-08&rft.volume=220&rft.issue=10&rft.spage=1629-1634&rft.epage=1629-1634&rft.eissn=0022-1899&rft.issn=0022-1899&rft.au=RYOM,%20L.&DILLING%20LUNDGREN,%20J.&REISS,%20P.&KIRK,%20O.&LAW,%20M.&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record